van Bremen K, Hoffmann C, Mauss S, et al. - Data on determinants of HBsAg loss were examined in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. It was reported that HBsAg loss had occurred in 66/359 (18%) individuals after a median follow‐up of 11 years. Nevertheless, it was noted that individuals were less likely to lose HBsAg if they had stage CDC C (p ≤ 0.001), lower CD4 gain (p=0.043), and were not receiving tenofovir disoproxil fumarate (TDF/FTC) (p=0.008) . In comparison with published data, long‐term TDF‐containing combination antiretroviral therapy (cART) seems to produce greater rates of HBsAg seroclearance for HBV monoinfected individuals. Nevertheless, the data revealed that late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.